Physician profile
Charles E D'Auria
NPI 1558324814
$16,363.38
in general payments reported to CMS, 2019-2025
53 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,041 · 2020: $2,151 · 2021: $2,114 · 2022: $1,983 · 2023: $2,538 · 2024: $2,320 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,068 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,067.93 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,500.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,478.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,476.98 | 2019-2025 | |
| Lilly USA, LLC | $1,286.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,271.51 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,247.52 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Amgen INC. | $771.71 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $739.10 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $733.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $601.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $586.52 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $415.22 | 2019-2025 | Eliquis, Camzyos |
| Allergan, INC. | $406.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.04 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $347.92 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles D'Auria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.